Loading stock data…
HIND
$2.27
Pre-MarketAs of Mar 25, 8:00 PM UTC
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets.
Recent News
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market
Investing.com -- U.S.-India focused clinical-stage pharmaceutical maker Vyome Holdings (Nasdaq: HIND) rang the opening bell at the NASDAQ on Friday, celebrating Indian Independence Day and its trading debut after a reverse merger with ReShape Lifesciences.